Arecor Therapeutics (LON:AREC) Issues Quarterly Earnings Results

Arecor Therapeutics (LON:AREC) posted its quarterly earnings data on Thursday. The company reported GBX (8) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Arecor Therapeutics had a return on equity of 14.26% and a net margin of 38.74%.

Arecor Therapeutics Price Performance

Shares of Arecor Therapeutics stock traded down GBX 1.50 during midday trading on Thursday, reaching GBX 71. The company had a trading volume of 73,229 shares, compared to its average volume of 24,898. Arecor Therapeutics has a 1-year low of GBX 56 and a 1-year high of GBX 95. The company has a current ratio of 4.35, a quick ratio of 6.24 and a debt-to-equity ratio of 1.52. The stock has a fifty day simple moving average of GBX 71.57 and a 200 day simple moving average of GBX 67.96. The company has a market capitalization of £26.81 million, a price-to-earnings ratio of 35.50 and a beta of -0.18.

About Arecor Therapeutics

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.